Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
2023 · Radiation Oncology · 25 citations
https://doi.org/10.1186/s13014-023-02308-2
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
11
Papers
404
Citations
7
h-index
6
i10-index
Jianfeng Peng is an academic researcher from Shandong Tumor Hospital. The author has contributed to research in topics: Renin-Angiotensin System Studies & Cardiovascular, Neuropeptides, and Oxidative Stress Research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 7, co-authored 10 publications.
https://doi.org/10.1186/s13014-023-02308-2
https://doi.org/10.1007/s12094-024-03499-0
Click to start Chat